// App-Quantinova.ai

TPS1140 : Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician-s choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

Researchers

Presenter

  • Edith A. Perez

Principal Investigators

  • Ahmad Awada

  • Joyce O'Shaughnessy

  • Hope S. Rugo

  • Christopher Twelves

  • Javier Cortes

  • San Francisco

  • California

Medical Centers

  • Institute Jules Bordet, Brussels, Belgium

  • Mayo Clinic, Jacksonville, FL

  • Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of Leeds, St Jamess University Hospital, Leeds, United Kingdom

  • Pathology Department, Vall d'Hebron University Hospital, Barcelona, Spain

Locations

  • United States

  • Spain

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Capecitabine

  • Gemcitabine

  • Ixabepilone

  • Vinorelbine

  • Paclitaxel

  • Docetaxel

  • Eribulin

  • etirinotecan pegol

  • taxane

Outcome

  • N/A

Study Design

  • randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved